A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis.
Leslie R HarroldPatrick ZuegerW Benjamin NowellTaylor BlachleyAmy SchraderPaul R LakinDavid CurtisLaura StradfordShilpa VenkatachalamNamita TundiaPankaj A PatelPublished in: Rheumatology and therapy (2023)
In this real-world cohort of patients with RA, treatment with upadacitinib was associated with early and significant improvement in RAPID3, pain, morning stiffness, and fatigue regardless of prior TNFi experience. Clinically meaningful improvement in RAPID3 patient-reported disease activity was observed as early as week 1, with continued improvement reported through week 12.